SK284837B6 - Trihydrát horečnatej soli S-omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie - Google Patents

Trihydrát horečnatej soli S-omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie Download PDF

Info

Publication number
SK284837B6
SK284837B6 SK1625-99A SK162599A SK284837B6 SK 284837 B6 SK284837 B6 SK 284837B6 SK 162599 A SK162599 A SK 162599A SK 284837 B6 SK284837 B6 SK 284837B6
Authority
SK
Slovakia
Prior art keywords
omeprazole
magnesium salt
magnesium
methoxy
salt
Prior art date
Application number
SK1625-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK162599A3 (en
Inventor
Hanna Cotton
Anders KRONSTR�M
Anders Mattson
Eva M�LLER
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK284837(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of SK162599A3 publication Critical patent/SK162599A3/sk
Publication of SK284837B6 publication Critical patent/SK284837B6/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
SK1625-99A 1997-05-30 1998-05-25 Trihydrát horečnatej soli S-omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie SK284837B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening
PCT/SE1998/000974 WO1998054171A1 (en) 1997-05-30 1998-05-25 Novel form of s-omeprazole

Publications (2)

Publication Number Publication Date
SK162599A3 SK162599A3 (en) 2000-06-12
SK284837B6 true SK284837B6 (sk) 2005-12-01

Family

ID=20407186

Family Applications (2)

Application Number Title Priority Date Filing Date
SK76-2005A SK285137B6 (sk) 1997-05-30 1998-05-25 Spôsob prípravy trihydrátu horečnatej soli S-omeprazolu, draselná soľ S-omeprazolu a spôsob jej prípravy
SK1625-99A SK284837B6 (sk) 1997-05-30 1998-05-25 Trihydrát horečnatej soli S-omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SK76-2005A SK285137B6 (sk) 1997-05-30 1998-05-25 Spôsob prípravy trihydrátu horečnatej soli S-omeprazolu, draselná soľ S-omeprazolu a spôsob jej prípravy

Country Status (44)

Country Link
US (6) US6369085B1 (et)
EP (2) EP1273581B1 (et)
JP (2) JP4002303B2 (et)
KR (2) KR100540720B1 (et)
CN (1) CN1161351C (et)
AR (2) AR012717A1 (et)
AT (2) ATE291574T1 (et)
AU (1) AU722839B2 (et)
BR (1) BR9809509A (et)
CA (2) CA2290963C (et)
CY (1) CY2012029I2 (et)
CZ (1) CZ297585B6 (et)
DE (3) DE69814069T3 (et)
DK (2) DK1273581T3 (et)
DZ (1) DZ2495A1 (et)
EE (1) EE03875B1 (et)
EG (1) EG24291A (et)
ES (2) ES2236407T3 (et)
HK (2) HK1051681A1 (et)
HR (1) HRP980263B1 (et)
HU (1) HU225987B1 (et)
ID (1) ID29306A (et)
IL (1) IL132947A0 (et)
IS (2) IS2142B (et)
LU (2) LU91871I2 (et)
MA (1) MA26500A1 (et)
ME (3) MEP18008A (et)
MY (2) MY127793A (et)
NO (3) NO317518B1 (et)
NZ (1) NZ500991A (et)
PL (1) PL193546B1 (et)
PT (2) PT1273581E (et)
RS (2) RS50005B (et)
RU (1) RU2184115C2 (et)
SA (2) SA98190280B1 (et)
SE (1) SE510650C2 (et)
SI (2) SI1273581T1 (et)
SK (2) SK285137B6 (et)
TN (1) TNSN98074A1 (et)
TR (1) TR199902934T2 (et)
TW (1) TW538040B (et)
UA (1) UA60334C2 (et)
WO (1) WO1998054171A1 (et)
ZA (1) ZA984179B (et)

Families Citing this family (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
PT909323E (pt) 1996-01-04 2007-06-04 Novartis Vaccines & Diagnostic ''bacterioferritina de helicobacter pilori''
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) * 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
PT1487818E (pt) 2002-03-05 2007-07-18 Astrazeneca Ab Sais de alquilamónio de omeprazole e esomeprazole
WO2003089408A2 (en) * 2002-04-22 2003-10-30 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
AU2003247729B2 (en) * 2002-06-27 2009-10-08 Dr. Reddy's Laboratories Limited A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
EP1515963B1 (en) * 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. A process for preparation of optically pure or optically enriched sulfoxide compounds, including amorphous esomeprazole and salts thereof
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
WO2004020436A1 (en) * 2002-08-30 2004-03-11 Reddy's Laboratories Limited Amorphous hydrates of esomeprazole magnesium and process for the preparation thereof
WO2004035052A1 (ja) * 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited 安定な固形製剤
WO2004037253A1 (en) * 2002-10-22 2004-05-06 Ranbaxy Laboratories Limited Amorphous form of esomeprazole salts
WO2004046134A2 (en) * 2002-11-18 2004-06-03 Dr. Reddy's Laboratories Limited Crystalline form ii of esomeprazole magnesium trihydrate and process for its preparation
CN1723208A (zh) * 2003-01-07 2006-01-18 兰贝克赛实验室有限公司 咪唑衍生物的镁盐
WO2004089935A1 (en) * 2003-04-10 2004-10-21 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
EP1633736A1 (en) 2003-05-05 2006-03-15 Ranbaxy Laboratories Limited Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
PT1651217E (pt) * 2003-07-23 2008-05-23 Nycomed Gmbh Sais alcalinos de inibidores da bomba de protões
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
BRPI0507837A (pt) * 2004-02-18 2007-07-10 Allergan Inc métodos e composições para a administração intravenosa de compostos relacionados a inibidores de bomba de prótons
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
MXPA06011820A (es) * 2004-04-16 2006-12-15 Santarus Inc Combinacion de inhibidor de bomba de proton, agente regulador del ph y agente procinetico.
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
JP5563735B2 (ja) 2004-06-16 2014-07-30 タケダ ファーマシューティカルズ ユー．エス．エー． インコーポレイティド Ｐｐｉ多回剤形
KR20130038949A (ko) * 2004-06-24 2013-04-18 아스트라제네카 아베 에소메프라졸 나트륨염의 제조에서 사용하기 위한 결정 변형의 제조를 위한 신규한 방법
ES2246149B1 (es) * 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006073779A1 (en) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Novel omeprazole forms and related methods
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
WO2006120520A1 (en) * 2005-05-06 2006-11-16 Glenmark Pharmaceuticals Limited Esomeprazole strontium salt, process for its preparation and pharmaceutical compositions containing same
US7563812B2 (en) 2005-06-15 2009-07-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
WO2007031845A2 (en) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Polymorphic forms of (s)-omeprazole magnesium salts and processes for their preparation
US7598273B2 (en) * 2005-10-06 2009-10-06 Auspex Pharmaceuticals, Inc Inhibitors of the gastric H+, K+-ATPase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
WO2007049914A1 (en) * 2005-10-26 2007-05-03 Hanmi Pharm. Co., Ltd. S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
US20100286208A1 (en) * 2006-06-21 2010-11-11 Bobba Venkata Siva Kumar Novel polymorph of esomeprazole potassium and process for its preparation
EP2068841B1 (en) 2006-10-05 2018-09-26 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
WO2008092939A2 (en) 2007-01-31 2008-08-07 Krka, Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic separation
ES2532854T3 (es) * 2007-02-21 2015-04-01 Cipla Limited Proceso para la preparación de esomeprazol magnésico dihidrato
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (en) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Esomeprazole salts and processes for preparation thereof
WO2008149204A1 (en) * 2007-06-07 2008-12-11 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
CN104069088A (zh) 2007-10-12 2014-10-01 武田制药北美公司 与食物摄入无关的治疗胃肠病症的方法
WO2009074997A2 (en) * 2007-12-10 2009-06-18 Lee Pharma Ltd. A novel process for the preparation of crystalline magnesium salt of (s)-omeprazole di hydrate
EP2240496A4 (en) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr PREPARATION OF MAGNESIUM OF ESOMEPRAZOLE AND ITS HYDRATES
US20090280175A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Proton Pump Inhibitor Tablets
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2143722A1 (en) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Process for preparation of esomeprazole sodium of high chemical purity and new forms of esomeprazole sodium
EP2147918A1 (en) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
JP2012502015A (ja) 2008-09-09 2012-01-26 アストラゼネカ・アクチエボラーグ 必要がある患者に医薬組成物を送達するための方法
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (en) 2009-02-24 2010-09-02 Cipla Limited Esomeprazole potassium polymorph and its preparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (en) 2009-04-24 2010-10-28 Rubicon Research Private Limited Oral pharmaceutical compositions of acid labile substances
WO2010150276A2 (en) * 2009-06-02 2010-12-29 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
KR20120030106A (ko) 2009-06-25 2012-03-27 아스트라제네카 아베 Ｎｓａｉｄ-연관된 궤양의 발생 위험이 있는 환자의 치료 방법
CN102638978A (zh) * 2009-06-25 2012-08-15 波曾公司 用于治疗需要阿司匹林治疗之患者的方法
WO2011012957A1 (en) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd An improved process for the preparation of esomeprazole magnesium dihydrate
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
SI2510089T1 (sl) 2009-12-08 2015-12-31 Codexis, Inc. Sinteza prazolnih spojin
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
US9267159B2 (en) 2010-12-08 2016-02-23 Codexis, Inc. Biocatalysts and methods for the synthesis of armodafinil
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN104844577A (zh) * 2011-07-31 2015-08-19 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102936238B (zh) * 2011-11-25 2015-02-18 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (en) * 2011-12-14 2013-06-20 Wockhardt Limited Pharmaceutical composition comprising esomeprazole magnesium dihydrate
CN104519888A (zh) 2011-12-28 2015-04-15 波曾公司 用于递送奥美拉唑和乙酰水杨酸的改良组合物和方法
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) * 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
EP3842575A4 (en) * 2018-08-21 2022-06-01 Towa Pharmaceutical Co., Ltd. SPECIFIC SHAPED CRYSTAL OF A COMPOUND AND METHOD OF PRODUCTION THEREOF
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
DE29522419U1 (de) 1994-07-08 2003-07-03 AstraZeneca AB, Södertälje Tablettierte Mehrfacheinheits-Dosisform
FR2722191B1 (fr) 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
ES2156605T3 (es) 1994-11-14 2001-07-01 Daiichi Seiyaku Co Procedimiento de preparacion de un 3,5-hidrato de dihidrocloruro de 3-(2-(4-(3-cloro-2-metilfenil)-1-piperazinil)etil)-5,6-dimetoxi-1-(4-imidazolilmetil)-1h-indazol.
GB9423970D0 (en) 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
US6747155B2 (en) * 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
TW538040B (en) 2003-06-21
SI1273581T1 (et) 2005-08-31
SK285137B6 (sk) 2006-07-07
JP2007161734A (ja) 2007-06-28
US7411070B2 (en) 2008-08-12
JP2002501529A (ja) 2002-01-15
HUP0001849A3 (en) 2003-02-28
DE69829511D1 (de) 2005-04-28
EE03875B1 (et) 2002-10-15
AR012717A1 (es) 2000-11-08
KR100527804B1 (ko) 2005-11-15
DE69814069T3 (de) 2014-03-27
HUP0001849A2 (hu) 2002-05-29
CY2012029I1 (el) 2015-08-05
KR20050042827A (ko) 2005-05-10
UA60334C2 (uk) 2003-10-15
AR059589A2 (es) 2008-04-16
KR20010013126A (ko) 2001-02-26
PL193546B1 (pl) 2007-02-28
IS2142B (is) 2006-09-15
US20120252847A1 (en) 2012-10-04
NO995852L (no) 2000-01-31
US20110130570A1 (en) 2011-06-02
LU92017I2 (fr) 2012-08-06
IS2774B (is) 2012-03-15
US20080255363A1 (en) 2008-10-16
HK1051681A1 (en) 2003-08-15
EP0984957A1 (en) 2000-03-15
TNSN98074A1 (fr) 2005-03-15
RU2184115C2 (ru) 2002-06-27
HU0001849D0 (et) 2002-05-29
ATE291574T1 (de) 2005-04-15
NO2012011I1 (no) 2012-06-18
LU91871I2 (fr) 2011-11-21
IL132947A0 (en) 2001-03-19
PT1273581E (pt) 2005-06-30
YU60999A (sh) 2002-03-18
ZA984179B (en) 1998-11-30
EP1273581A1 (en) 2003-01-08
HRP980263B1 (en) 2002-02-28
CA2290963A1 (en) 1998-12-03
IS5272A (is) 1999-11-25
CN1258295A (zh) 2000-06-28
BR9809509A (pt) 2000-06-20
DE69829511T2 (de) 2006-02-16
SK162599A3 (en) 2000-06-12
US6369085B1 (en) 2002-04-09
US20050075369A1 (en) 2005-04-07
EP0984957B1 (en) 2003-05-02
MY120745A (en) 2005-11-30
RS20070459A (en) 2008-06-05
ES2236407T3 (es) 2005-07-16
DE122012000017I1 (de) 2012-08-16
ATE239011T1 (de) 2003-05-15
PT984957E (pt) 2003-07-31
US8076361B2 (en) 2011-12-13
DZ2495A1 (fr) 2003-01-25
AU722839B2 (en) 2000-08-10
ES2195345T3 (es) 2003-12-01
NZ500991A (en) 2001-05-25
TR199902934T2 (xx) 2000-04-21
PL337180A1 (en) 2000-08-14
SA05260296B1 (ar) 2008-04-16
EP1273581B1 (en) 2005-03-23
CY2012029I2 (el) 2015-08-05
CA2521391A1 (en) 1998-12-03
US8466175B2 (en) 2013-06-18
HU225987B1 (en) 2008-02-28
JP4002303B2 (ja) 2007-10-31
MEP24908A (en) 2010-10-10
CA2521391C (en) 2009-09-29
MY127793A (en) 2006-12-29
RS50067B (sr) 2009-01-22
SI0984957T1 (en) 2003-10-31
MA26500A1 (fr) 2004-12-20
NO995852D0 (no) 1999-11-29
AU7793598A (en) 1998-12-30
DK0984957T3 (da) 2003-06-30
DE69814069D1 (de) 2003-06-05
EP0984957B3 (en) 2013-09-18
NO2011010I1 (no) 2011-06-20
ES2195345T7 (es) 2014-01-15
DE69814069T2 (de) 2004-04-01
CN1161351C (zh) 2004-08-11
HRP980263A2 (en) 1999-02-28
SA98190280B1 (ar) 2006-07-04
WO1998054171A8 (en) 1999-12-23
IS8368A (is) 2006-03-22
US20020198239A1 (en) 2002-12-26
CA2290963C (en) 2006-03-28
CZ297585B6 (cs) 2007-01-10
ME00198B (me) 2011-02-10
DK1273581T3 (da) 2005-06-06
SE9702065D0 (sv) 1997-05-30
EE9900550A (et) 2000-06-15
HK1025962A1 (en) 2000-12-01
MEP18008A (en) 2010-10-10
SE510650C2 (sv) 1999-06-14
EG24291A (en) 2009-01-08
KR100540720B1 (ko) 2006-01-12
US6677455B2 (en) 2004-01-13
US7745466B2 (en) 2010-06-29
NO317518B1 (no) 2004-11-08
SE9702065L (sv) 1998-12-01
WO1998054171A1 (en) 1998-12-03
ID29306A (id) 2001-08-16
RS50005B (sr) 2008-09-29

Similar Documents

Publication Publication Date Title
SK284837B6 (sk) Trihydrát horečnatej soli S-omeprazolu, spôsob jeho prípravy, farmaceutická kompozícia s jeho obsahom a jeho použitie
EP1149090B1 (en) Novel crystalline form of the potassium salt of (s)-omeprazole
US6747155B2 (en) Process
CZ296154B6 (cs) Trihydrát horecnaté soli S-omeprazolu, zpusob jeho prípravy a farmaceutický prostredek s jeho obsahem
MXPA99010945A (en) Novel form of s
MXPA01007516A (en) Potassium salt of (s

Legal Events

Date Code Title Description
SPCF Filing of an spc

Free format text: PRODUCT NAME: NAPROXEN A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 29/0782/10-S 20101112; FIRST REGISTRATION: GB PL 17901/0263 - 0001 20101105

Spc suppl protection certif: 5-2011

Filing date: 20110510

SPCF Filing of an spc

Free format text: PRODUCT NAME: KYSELINA ACETYLSALICYLOVA A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 5402359 - 5402375 20110812; FIRST REGISTRATION: PT 5402359 - 5402375 20110812

Spc suppl protection certif: 5009-2012

Filing date: 20120517

SPCF Filing of an spc

Free format text: PRODUCT NAME: KYSELINA ACETYLSALICYLOVA A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 41/513/11-S 20110818; FIRST REGISTRATION: PT 5402359 - 5402375 20110812

Spc suppl protection certif: 5009-2012

Filing date: 20120517

Free format text: PRODUCT NAME: NAPROXEN A EZOMEPRAZOL; NAT. REGISTRATION NO/DATE: 29/0782/10-S 20101112; FIRST REGISTRATION: GB PL 17901/0263 - 0001 20101105

Spc suppl protection certif: 5-2011

Filing date: 20110510

MK4A Patent expired

Expiry date: 20180525